A cost-effectiveness analysis of preimplantation genetic testing for aneuploidy (PGT-A) for up to three complete assisted reproductive technology cycles in women of advanced maternal age

被引:23
作者
Lee, Evelyn [1 ]
Costello, Michael F. [2 ]
Botha, Willings C. [3 ]
Illingworth, Peter [4 ]
Chambers, Georgina M. [5 ]
机构
[1] Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW, Australia
[2] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia
[3] Univ New South Wales, Ctr Big Data Res Hlth, Natl Perinatal Epidemiol & Stat, Sydney, NSW, Australia
[4] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia
[5] IVF Australia Pty Ltd, Sydney, NSW, Australia
关键词
aneuploidy; assisted reproductive technology; cost-effectiveness analysis; cumulative live-birth rate; preimplantation genetic diagnosis;
D O I
10.1111/ajo.12988
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background Current evidence suggests that preimplantation genetic testing for aneuploidy (PGT-A) used during assisted reproductive technology improves per-cycle live-birth rates but cumulative live-birth rate (CLBR) was similar to a strategy of morphological assessment (MA) of embryos. No study has assessed the cost-effectiveness of repeated cycles with PGT-A using longitudinal patient-level data. Aim To assess the cost-effectiveness of repeated cycles with PGT-A compared to MA of embryos in older women. Materials and Methods Micro-costing methods were used to value direct resource consumption of 2093 assisted reproductive technology-naive women aged >= 37 years undergoing up to three 'complete assisted reproductive technology cycles' (fresh plus cryopreserved embryos) with either PGT-A or MA in an Australian clinic between 2011 and 2014. Incremental cost-effective ratios were calculated from healthcare and patient perspectives with uncertainty assessed using non-parametric bootstrap methods. Cost-effectiveness acceptability curves were constructed to evaluate the probability of PGT-A being cost-effective over a range of willingness-to-pay thresholds. Results The CLBR and mean healthcare costs per patient were 30.90% and $22 962 for the PGT-A group, and 26.77% and $21 801 for the MA group, yielding an incremental cost-effective ratio of $28 103 for an additional live birth with PGT-A. At a willingness-to-pay threshold of $50 000 and above, there is more than an 80% probability of PGT-A being cost-effective from the healthcare perspective and a 50% likelihood from a patient perspective. Conclusion This is the first study to use real-world patient-level data to assess the cost-effectiveness of PGT-A in older women from the healthcare and patient perspectives. The findings contribute to the ongoing debate on the role of PGT-A in clinical practice.
引用
收藏
页码:573 / 579
页数:7
相关论文
共 30 条
  • [1] The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion
    Penzias A.
    Bendikson K.
    Butts S.
    Coutifaris C.
    Falcone T.
    Fossum G.
    Gitlin S.
    Gracia C.
    Hansen K.
    La Barbera A.
    Mersereau J.
    Odem R.
    Paulson R.
    Pfeifer S.
    Pisarska M.
    Rebar R.
    Reindollar R.
    Rosen M.
    Sandlow J.
    Vernon M.
    Widra E.
    [J]. FERTILITY AND STERILITY, 2018, 109 (03) : 429 - 436
  • [2] Australian Government Department of Health and Ageing (DoHA), 2015, SCHED PHARM BEN EFF
  • [3] Societal preferences for fertility treatment in Australia: a stated preference discrete choice experiment
    Botha, Willings
    Donnolley, Natasha
    Shanahan, Marian
    Norma, Robert J.
    Chambers, Georgina M.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 95 - 107
  • [4] Assessment of the societal and individual preferences for fertility treatment in Australia: study protocol for stated preference discrete choice experiments
    Botha, Willings
    Donnolley, Natasha
    Shanahan, Marian
    Chambers, Georgina M.
    [J]. BMJ OPEN, 2018, 8 (02):
  • [5] The death of cost-minimization analysis?
    Briggs, AH
    O'Brien, BJ
    [J]. HEALTH ECONOMICS, 2001, 10 (02) : 179 - 184
  • [6] Briggs AH, 2006, Decision Modelling for Health Economic Evaluation
  • [7] Acceptable cost for the patient and society
    Chambers, Georgina M.
    Adamson, G. David
    Eijkemans, Marinus J. C.
    [J]. FERTILITY AND STERILITY, 2013, 100 (02) : 319 - 327
  • [8] Cost-effectiveness of preimplantation genetic screening for women older than 37 undergoing in vitro fertilization
    Collins, Stephen C.
    Xu, Xiao
    Mak, Winifred
    [J]. JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2017, 34 (11) : 1515 - 1522
  • [9] COST-MINIMISATION ANALYSIS VERSUS COST-EFFECTIVENESS ANALYSIS, REVISITED
    Dakin, Helen
    Wordsworth, Sarah
    [J]. HEALTH ECONOMICS, 2013, 22 (01) : 22 - 34
  • [10] Devlin Nancy, 2003, Hum Fertil (Camb), V6 Suppl 1, pS2, DOI 10.1080/1464770312331369153